Evidence map›Paper›PMID 23377227›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2013

Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

R E A Tjon Pian Gi, T Ilmarinen, E R van den Heuvel, L M Aaltonen, J Andersen, J W Brunings, M Chirila, A Dietz, F Ferran Vilà, G Friedrich and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Off-label drugs in laryngology- what should the doctor and the patient know about such therapies? A consensus statement of the European Laryngological Society.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  5. Article
  6. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. The clinical course of recurrent respiratory papillomatosis after the use of cidofovir is influenced by multiple factors.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2015
    Article
  12. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2014
    Review
  13. Use of cidofovir in HPV patients with recurrent respiratory papillomatosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2014
    Article
  14. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2014
    Article
  15. Pathologies of the larynx and trachea in childhood.GMS current topics in otorhinolaryngology, head and neck surgery · 2014
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 11 countries.

R E A Tjon Pian GiDepartment of Otorhinolaryngology Head and Neck Surgery, University of Groningen, University Medical Center Groningen, PO box 30001, 9700 RB Groningen, The Netherlands. r.e.a.tjonpiangi@umcg.nl
T Ilmarinen
E R van den Heuvel
L M Aaltonen
J Andersen
J W Brunings
M Chirila
A Dietz
F Ferran Vilà
G Friedrich
H H W de Gier
W Golusinski
M Graupp
A Hantzakos
R Horcasitas
J Jackowska
J C Koelmel
G Lawson
F Lindner
M Remacle
C Sittel
V Weichbold
M Wierzbicka
F G Dikkers
Helsinki University Hospital · FIKlinikum Stuttgart · DELeipzig University · DEMedical University of Graz · ATPoznan University of Medical Sciences · PLUCLouvain · BEUniversity of Groningen · NLAutonomous University of Chihuahua · MXErasmus University Rotterdam · NLGreater Poland Cancer Center · PLGrigore T. Popa University of Medicine and Pharmacy · ROHospital General de Catalunya · ESInnsbruck Medical University · ATMaastricht University Medical Centre · NLNational and Kapodistrian University of Athens · GRRegionshospitalet Viborg · DKUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intralesional use of cidofovir (Vistide(®)) has been one of the mainstays of adjuvant therapy in patients with recurrent respiratory papillomatosis (RRP) since 1998. In 2011, a communication provided by the producer of cidofovir addressed very serious side effects concerning its off-label use. As this was a general warning, it was inconclusive whether this would account for its use in RRP. The aim of this study is to determine whether nephrotoxic, neutropenic, or oncogenic side effects have occurred after intralesional use of cidofovir in patients with RRP. Update of recent developments in RRP, a multicentre questionnaire and a multicentre retrospective chart review. Sixteen hospitals from eleven countries worldwide submitted records of 635 RRP patients, of whom 275 were treated with cidofovir. RRP patients received a median of three intralesional injections (interquartile range 2-6). There were no statistical differences in occurrence of neutropenia or renal dysfunction before and after cidofovir. There was no statistical difference in occurrence of upper airway and tracheal malignancies between the cidofovir and the non-cidofovir group. In this retrospective patient chart review, no clinical evidence was found for more long-term nephrotoxicity, neutropenia or laryngeal malignancies after the administration of intralesional cidofovir in RRP patients.

Indexed as

Antiviral AgentsCidofovirCombined Modality TherapyCytosineFemaleHead and Neck NeoplasmsHumansInjections, IntralesionalMaleNeutropeniaOff-Label UseOrganophosphonatesPapillomavirus InfectionsRenal InsufficiencyRespiratory Tract InfectionsRetrospective StudiesAntiviral AgentsCidofovirCytosineOrganophosphonates

Identifiers

PMID23377227
OpenAlexW2139397517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.